B. Riley Weighs in on Veru’s Q1 Earnings (NASDAQ:VERU)

Veru Inc. (NASDAQ:VERU) – Investment analysts at B. Riley issued their Q1 2025 earnings per share estimates for Veru in a report issued on Thursday, January 9th. B. Riley analyst W. Wood anticipates that the company will post earnings of ($0.08) per share for the quarter. The consensus estimate for Veru’s current full-year earnings is ($0.30) per share. B. Riley also issued estimates for Veru’s Q2 2025 earnings at ($0.05) EPS.

Several other equities analysts also recently commented on VERU. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Veru in a research report on Thursday, January 2nd. Oppenheimer reissued an “outperform” rating and issued a $5.00 price objective on shares of Veru in a report on Tuesday, November 5th.

Veru Stock Performance

NASDAQ VERU opened at $0.74 on Monday. The stock has a market cap of $108.84 million, a PE ratio of -1.55 and a beta of -0.53. The firm has a 50-day moving average of $0.69 and a 200-day moving average of $0.80. Veru has a 52-week low of $0.36 and a 52-week high of $1.92.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Monday, December 16th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%.

Hedge Funds Weigh In On Veru

Several hedge funds have recently bought and sold shares of the company. Zacks Investment Management bought a new position in Veru in the third quarter valued at approximately $25,000. Gladstone Institutional Advisory LLC grew its position in Veru by 34.2% in the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $44,000 after acquiring an additional 14,500 shares during the last quarter. Weaver Consulting Group lifted its holdings in shares of Veru by 41.0% in the fourth quarter. Weaver Consulting Group now owns 69,705 shares of the company’s stock worth $45,000 after acquiring an additional 20,280 shares during the last quarter. SG Americas Securities LLC increased its position in Veru by 185.9% during the 3rd quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock worth $51,000 after purchasing an additional 42,997 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Veru by 142.8% during the third quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock worth $74,000 after buying an additional 56,736 shares during the last quarter. 47.16% of the stock is owned by institutional investors.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.